Founded in 2013, Jounce Therapeutics is focused on discovering and developing first-in-class cancer immunotherapies. Their proprietary product engine enables a biomarker-driven approach, potentially leading to more durable responses and improved quality of life for patients. With a suite of integrated technologies, Jounce comprehensively analyzes the cellular and molecular composition of tumors through their Translational Science Platform. They have multiple development stage programs, including their highest priority program, JTX-8064, which reprograms immune-suppressive tumor-associated macrophages. They are also advancing vopratelimab, a monoclonal antibody that activates ICOS, and JTX-4014, a PD-1 inhibitor, in clinical trials. Jounce has exclusively licensed JTX-1811, a monoclonal antibody targeting CCR8, to Gilead Sciences, Inc.